Screening and Risk Reduction Strategies for Breast Cancer. Imaging Modality and Risk-Reduction Approaches

1. Introduction of the whole issue

2. Breast cancer epidemiology: incidence, risks and subtype

3. Personalized genetic breast cancer risk estimation with polygenic risk scores

4. Mathematical model forassessing breast cancer risk

5. Cost-effectiveness Analysis of multigene testing

6. Hereditary breast cancer: Its biology, subtype and clinical phenotype

7. Surgical risk reduction of breast cancer

8. Medical risk reduction of breast cancer

9. Screening for breast cancer with mammography

10. Breast cancer screening: Weighing the benefits and harms

11. Breast cancer screening according to individual risk

12. MRI: Detection of noninvasive diseases

13. Significance of MRI for women having dense breasts 

14. Ultrasound: screening of breast cancer

15. Detection of breast cancer by PET

16. Radiowave mammography

17. Photoacoustic imaging of breast cancer

This book provides readers with the most up-to-date practical information on breast cancer screening. Since breast cancers are highly heterogeneous, time to clinical onset from the initial carcinogenesis differs diversely between cancers. Pathological germline variants and driver mutations cause a high lifetime risk of breast cancer. The lifetime risks are various according to what genes are pathologically dysfunctional. Integrated omics and imaging technologies have established varying tumour characteristics. Thus, this book suggests that a more individualised scheme is required to improve breast cancer screening.

 

A key aim is to demonstrate how multiple diagnostic imaging modalities such as mammography, ultrasonography, MRI, PET and dbPET improve breast cancer screening accuracy. Mammography screening alone may have a limited impact on breast cancer risk prediction. These issues are crucial to discuss. Clinical experts recommend that new modalities be incorporated for women with dense breasts, like ultrasonography, dynamic mammography, MRI and maybe breast-dedicated PET. Topics on these modalities are going to be summarized in this book. An in-depth review of these modalities is summarised in this book. In addition, new diagnostic modalities, including risk assessment tools, multi-cancer early detection tests using liquid biopsy, the role of protein biomarkers in breast cancer risk screening, challenges, and hopes for future advances, are also covered in this book.

 

 

AUTHOR

 

Masakazu Toi, Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.